AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Pharmacological Intervention in Insulin Resistance Targeting Autonomic Nerve Activity
Early Phase 1
Completed
- Conditions
- Insulin Resistance
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2009-03-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT00689208
- Locations
- 🇸🇪
Research Site, Göteborg, Sweden
Study Comparing a Fixed-Dose Capsule of Esomeprazole 40mg and LDA 325mg With Free Combination
Phase 1
Completed
- Conditions
- UlcersUpper GI Symptoms
- Interventions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 84
- Registration Number
- NCT00688428
Drug Interaction Study Between AZD3480 and Warfarin
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2009-07-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 26
- Registration Number
- NCT00689637
- Locations
- 🇸🇪
Research SIte, Uppsala, Sweden
Drug Interaction Study Between AZD3480 and Aripiprazole in Healthy Subjects
Phase 1
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2009-07-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 52
- Registration Number
- NCT00689559
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Effects of Crestor on Inflammation of Atherosclerotic Plaques
Early Phase 1
Completed
- Conditions
- AtherosclerosisInflammatory Activity in Carotid Arteries
- Interventions
- Drug: placebo
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2009-06-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 74
- Registration Number
- NCT00689416
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Gastroesophageal Reflux Disease (GERD) Segmentation: Document How Swiss General Practitioners (GPs) Allocate Their GERD Patients to the Three GERD Patient Segments
Completed
- Conditions
- GERD
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2010-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2912
- Registration Number
- NCT00688675
- Locations
- 🇨🇭
Research Site, Aarau, Switzerland
Study of an Extended Release (ER) Tablet, Single and Repeated Dosing
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 94
- Registration Number
- NCT00689039
- Locations
- 🇸🇪
Research Site, Göteborg, Sweden
Study to Compare Different Formulations of AZD3355
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT00688402
- Locations
- 🇸🇪
Research Site, Varvsgatan, Lulea, Sweden
Regional Observatory on Metabolic Syndrome- LAZIO
Completed
- Conditions
- Metabolic Syndrome
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1574
- Registration Number
- NCT00689455
- Locations
- 🇮🇹
Research Site, Viterbo, Italy
Evaluate Different Extended-release (ER) Tablets/Capsules of AZD1305
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 50
- Registration Number
- NCT00689403
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath